Press releases

Disruptive Pharma AB (publ), formerly Guard Therapeutics International AB (publ), (“Disruptive Pharma” or the “Company”) will ring the opening bell at Nasdaq Stockholm on 21 August 2026. On the same day, the Company’s shares will begin trading under the new ticker symbol DPHA, replacing GUARD. The bell-ringing ceremony marks the...

During summer 2026, Disruptive Pharma welcomed Johannes Schwarz, a Master's student at Uppsala University, to our labs in Uppsala through the SweDeliver Summer Internship programme. During his internship, Johannes explored how different formulations influence the tableting process and the properties of the final tablets. The project provided...

Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the “Company”) today announced that it has initiated a structured transaction process regarding the so-called GTX platform, consisting of therapeutic peptides based on the endogenous protein alpha-1-microglobulin (A1M), together with related intellectual property and...

In this Swedish-language presentation, CEO Peter Åsberg gives an update on Disruptive Pharma, the company’s proprietary Formulite® technology platform, and the next phase of development. Watch the presentation on YouTube: https://www.youtube.com/watch?v=IWPt4QuAQG8&t=87s

In this Swedish-language interview, Disruptive Pharma and Guard Therapeutics discuss the proposed reverse takeover announced on 10 June 2026, including the background to the transaction and what the planned combination could mean for Disruptive Pharma's continued development. Watch the interview on YouTube: https://www.youtube.com/watch?v=nYjn5G9jffY&t=74s...